Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Assistance Publique - Hôpitaux de Paris
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05476991CT.gov Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | — | Recruiting | — | — | — |
NCT04948749CT.gov Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial | — | Recruiting | — | — | — |
NCT03062462CT.gov Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Coronary Artery Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ticagrelor (this asset) | Assistance Publique - Hôpitaux de Paris | P3 | BB · 64 |
| Aspirin | Rajaie Cardiovascular Medical and Research Center | P4 | BBB |
| Ezetimibe | Canadian Collaborative Research Network | P4 | BBB |
| Ranolazine | OBS Pakistan | P4 | BBB |
| Simvastatin | University of Washington | P4 | BBB |
| Rivaroxaban | Sheffield Teaching Hospitals NHS Foundation Trust | P4 | BBB |
| Pitavastatin | Yokohama City University Medical Center | P4 | BBB |
| Clopidogrel | Beijing Tiantan Hospital | P4 | BB |
| Fluvastatin | Yokohama City University Medical Center | P4 | BB |
+40 more in the Coronary Artery Disorder cohort
Other indications for Ticagrelor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myocardial Infarction | — | P4 | BBB · 78 |
| Ischemic Stroke | — | P4 | BBB · 76 |
| Transient Ischemic Attack | — | P3 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ticagrelor in Coronary Artery Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ticagrelor-coronary-artery-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →